Loading...
XASESCPX
Market cap8mUSD
Dec 23, Last price  
0.31USD
1D
-8.60%
1Q
-58.74%
Jan 2017
-96.37%
IPO
-96.66%
Name

NightHawk Biosciences Inc

Chart & Performance

D1W1MN
XASE:SCPX chart
P/E
P/S
1.35
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
115.63%
Rev. gr., 5y
31.52%
Revenues
6m
+183.08%
187,7873,110000341,6431,519,9435,793,8493,049,1042,947,9692,112,8065,980,993
Net income
-44m
L+23.90%
-2,104,884-2,420,200-8,711,348-11,788,817-20,295,000-12,573,952-11,841,671-15,733,854-20,384,716-27,694,186-35,400,807-43,862,197
CFO
-6m
L-85.05%
-1,649,099-2,073,675-6,388,868-9,829,427-17,447,000-13,523,717-6,303,672-21,711,691-12,837,650-22,021,359-38,128,906-5,700,364

Profile

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
IPO date
Jul 24, 2013
Employees
77
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,981
183.08%
2,113
-28.33%
Cost of revenue
50,993
36,341
Unusual Expense (Income)
NOPBT
(45,012)
(34,228)
NOPBT Margin
Operating Taxes
(3,289)
(146)
Tax Rate
NOPAT
(41,723)
(34,082)
Net income
(43,862)
23.90%
(35,401)
27.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
60
26,304
BB yield
-0.29%
-34.73%
Debt
Debt current
791
611
Long-term debt
17,991
3,243
Deferred revenue
32
35
Other long-term liabilities
(31,037)
2,640
Net debt
10,839
(93,843)
Cash flow
Cash from operating activities
(5,700)
(38,129)
CAPEX
(20,118)
(1,905)
Cash from investing activities
10,992
9,770
Cash from financing activities
(4,907)
25,490
FCF
(79,126)
(35,535)
Balance
Cash
44,272
96,379
Long term investments
(36,328)
1,318
Excess cash
7,645
97,592
Stockholders' equity
(210,583)
(166,857)
Invested Capital
260,274
283,297
ROIC
ROCE
EV
Common stock shares outstanding
25,606
24,914
Price
0.81
-73.52%
3.04
-43.28%
Market cap
20,616
-72.78%
75,738
-11.59%
EV
29,968
(19,179)
EBITDA
(41,867)
(33,621)
EV/EBITDA
0.57
Interest
2,821
Interest/NOPBT